重症监护病房患者医院获得性血流感染的流行病学与结局:EUROBACT-2国际队列研究
EUROBACT-2是一项前瞻性国际队列研究,纳入2019年6月至2021年2月间52个国家333个ICU的2600例成人医院获得性血流感染患者。78%为ICU获得性,最常见感染源为肺炎(26.7%)和血管内导管(26.4%),最常见病原体为革兰阴性菌(59.0%),碳青霉烯耐药和难治耐药(DTR)分别占37.8%和23.5%。抗菌药物耐药与充分抗菌治疗延迟相关,仅51.5%在24小时内获得充分治疗,52.5%需要感染源控制但18.2%未实现。病死率37.1%,第28天仅16.1%存活出院。
要点
- 2600例ICU医院获得性血流感染中78%为ICU获得性,诊断时中位SOFA评分为8分(IQR 5;11)。
- 最常见病原体为革兰阴性菌(59.0%),其中肺炎克雷伯菌27.9%、不动杆菌属20.3%、大肠埃希菌15.8%、假单胞菌属14.3%。
- 碳青霉烯耐药率分别为肺炎克雷伯菌37.8%、不动杆菌属84.6%、大肠埃希菌7.4%、假单胞菌属33.2%;DTR占23.5%,泛耐药占1.5%。
- 仅51.5%在24小时内接受充分抗菌治疗,抗菌药物耐药与充分治疗延迟相关;52.5%需要感染源控制但18.2%未实现。
- 病死率37.1%,第28天仅16.1%存活出院。
适用人群与场景
- 成人(≥18岁)ICU患者,于2019年6月至2021年2月期间发生医院获得性血流感染。
处置流程与药物剂量
- 感染源控制:52.5%的患者需要感染源控制,但18.2%未实现。
研究设计与关键结果
- 研究类型:前瞻性国际队列研究;样本量:2600例患者,来自52个国家333个ICU。
- 78%的医院获得性血流感染为ICU获得性;诊断时中位SOFA评分为8分(IQR 5;11)。
- 最常见感染源:肺炎(26.7%)、血管内导管(26.4%)。
- 最常见病原体:革兰阴性菌(59.0%),其中肺炎克雷伯菌27.9%、不动杆菌属20.3%、大肠埃希菌15.8%、假单胞菌属14.3%。
- 碳青霉烯耐药率:肺炎克雷伯菌37.8%、不动杆菌属84.6%、大肠埃希菌7.4%、假单胞菌属33.2%;DTR占23.5%,泛耐药占1.5%。
- 24小时内充分抗菌治疗的比例为51.5%;抗菌药物耐药与充分抗菌治疗延迟相关。
- 感染源控制:52.5%需要感染源控制,18.2%未实现。
- 结局:病死率37.1%,第28天存活出院率16.1%。
证据类型、等级与局限
- 证据类型:前瞻性国际队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,预防抗菌药物耐药、关注充分抗菌治疗和感染源控制对于优化患者管理和结局非常重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: In the critically ill, hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality. Granular data are required for optimizing management, and developing guidelines and clinical trials.
METHODS: We carried out a prospective international cohort study of adult patients (≥ 18 years of age) with HA-BSI treated in intensive care units (ICUs) between June 2019 and February 2021.
RESULTS: 2600 patients from 333 ICUs in 52 countries were included. 78% HA-BSI were ICU-acquired. Median Sequential Organ Failure Assessment (SOFA) score was 8 [IQR 5; 11] at HA-BSI diagnosis. Most frequent sources of infection included pneumonia (26.7%) and intravascular catheters (26.4%). Most frequent pathogens were Gram-negative bacteria (59.0%), predominantly Klebsiella spp. (27.9%), Acinetobacter spp. (20.3%), Escherichia coli (15.8%), and Pseudomonas spp. (14.3%). Carbapenem resistance was present in 37.8%, 84.6%, 7.4%, and 33.2%, respectively. Difficult-to-treat resistance (DTR) was present in 23.5% and pan-drug resistance in 1.5%. Antimicrobial therapy was deemed adequate within 24 h for 51.5%. Antimicrobial resistance was associated with longer delays to adequate antimicrobial therapy. Source control was needed in 52.5% but not achieved in 18.2%. Mortality was 37.1%, and only 16.1% had been discharged alive from hospital by day-28.
CONCLUSIONS: HA-BSI was frequently caused by Gram-negative, carbapenem-resistant and DTR pathogens. Antimicrobial resistance led to delays in adequate antimicrobial therapy. Mortality was high, and at day-28 only a minority of the patients were discharged alive from the hospital. Prevention of antimicrobial resistance and focusing on adequate antimicrobial therapy and source control are important to optimize patient management and outcomes.
参考来源
- Tabah A, Buetti N, Staiquly Q, et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023. PMID: 36764959. doi:10.1007/s00134-022-06944-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。